Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “SION”

1,496 pharma patents match "SION" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 1,496
Index total 30,257
Page 30 / 63

Quick answer

This filtered view shows 1,496 pharmaceutical patents matching "SION" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

1,496 results for “SION” · 30,257 patents in full index Clear search

  1. US 9926602

    Recurrent gene fusions in prostate cancer

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Mar 27, 2018 · Expires Mar 22, 2038

    granted
  2. US 9920109

    Serpin fusion polypeptides and methods of purification thereof

    Inhibrx, Inc. · Granted Mar 20, 2018 · Expires Mar 15, 2038

    granted
  3. US 9914927

    RNAi inhibition of alpha-ENaC expression

    Arrowhead Pharmaceuticals, Inc. · Granted Mar 13, 2018 · Expires Mar 8, 2038

    granted
  4. US 9914765

    WAP domain fusion polypeptides and methods of use thereof

    Inhibrx, Inc. · Granted Mar 13, 2018 · Expires Mar 8, 2038

    granted
  5. US 9909124

    Compounds and methods for modulating apolipoprotein C-III expression for improving a diabetic profile

    Ionis Pharmaceuticals, Inc. · Granted Mar 6, 2018 · Expires Mar 1, 2038

    granted
  6. US 9902955

    Method and medicament for inhibiting the expression of a given gene

    Alnylam Pharmaceuticals, Inc. · Granted Feb 27, 2018 · Expires Feb 22, 2038

    granted
  7. US 9899614

    Phosphorescent tetradentate metal complexes having modified emission spectra

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Feb 20, 2018 · Expires Feb 15, 2038

    granted
  8. US 9889160

    Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene

    Precision BioSciences, Inc. · Granted Feb 13, 2018 · Expires Feb 8, 2038

    granted
  9. US 9889161

    Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene

    Precision BioSciences, Inc. · Granted Feb 13, 2018 · Expires Feb 8, 2038

    granted
  10. US 9884072

    Methods and compositions for modulating apolipoprotein (a) expression

    Ionis Pharmaceuticals, Inc. · Granted Feb 6, 2018 · Expires Feb 1, 2038

    granted
  11. US 9885051

    Regulated expression of antigen and/or regulated attenuation to enhance vaccine immunogenicity and/or safety

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Feb 6, 2018 · Expires Feb 1, 2038

    granted
  12. US 9885045

    Methods and compositions for modulating apolipoprotein (a) expression

    Ionis Pharmaceuticals, Inc. · Granted Feb 6, 2018 · Expires Feb 1, 2038

    granted
  13. US 9885047

    Modulation of TMPRSS6 expression

    Ionis Pharmaceuticals, Inc. · Granted Feb 6, 2018 · Expires Feb 1, 2038

    granted
  14. US 9877952

    Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy

    PTC THERAPEUTICS, INC. · Granted Jan 30, 2018 · Expires Jan 25, 2038

    granted
  15. US 9873875

    Methods and compositions for the specific inhibition of gene expression by double-stranded RNA

    INTEGRATED DNA TECHNOLOGIES, INC. · Granted Jan 23, 2018 · Expires Jan 18, 2038

    granted
  16. US 9868943

    Enhanced staphylolytic activity of the Staphylococcus aureus bacteriophage vB—SauS-philPLA88 virion-associated peptidoglycan hydrolase HydH5: fusions, deletions and synergy with LysH5

    The United States of America, as represented by the Secretary of Agriculture · Granted Jan 16, 2018 · Expires Jan 11, 2038

    granted
  17. US 9867830

    Use of (2R, 6R)-hydroxynorketamine, (S)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (R,S)-ketamine in the treatment of depression and neuropathic pain

    THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH · Granted Jan 16, 2018 · Expires Jan 11, 2038

    granted
  18. US 9868950

    Lipid formulated compositions and methods for inhibiting expression of serum amyloid A gene

    Alnylam Pharmaceuticals, Inc. · Granted Jan 16, 2018 · Expires Jan 11, 2038

    granted
  19. US 9862746

    Compositions and methods relating to hindering DOT1L recruitment by MLL-fusion proteins

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Jan 9, 2018 · Expires Jan 4, 2038

    granted
  20. US 9856310

    UTI fusion proteins

    Takeda Pharmaceutical Company Limited · Granted Jan 2, 2018 · Expires Dec 28, 2037

    granted
  21. US 9856313

    Epitope of RSV fusion protein and antibody recognizing the same

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jan 2, 2018 · Expires Dec 28, 2037

    granted
  22. US 9849100

    Pharmaceutical compositions suitable for parenteral administration comprising aqueous suspensions of benzylamine derivatives having low solubilities

    KalVista Pharmaceuticals Limited · Granted Dec 26, 2017 · Expires Dec 21, 2037

    granted
  23. US 9845346

    Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof

    BIOMARIN PHARMACEUTICAL INC. · Granted Dec 19, 2017 · Expires Dec 14, 2037

    granted
  24. US 9844611

    Tissue-separating fatty acid adhesion barrier

    ATRIUM MEDICAL CORPORATION · Granted Dec 19, 2017 · Expires Dec 14, 2037

    granted